The impact of spleen metabolic tumor volume on total metabolic tumor volume and prognosis in patients with follicular lymphoma enrolled in FOLL 12 trial

Introduction and Aim: Recently, in an ancillary study of FOLL12 trial (NCT02063685), total Metabolic Tumor Volume (tMTV) assessed before treatment has been demonstrated to be independent predictor PFS patients receiving frontline immune chemotherapy (1). During the segmentation procedure, it observed that frequently spleen MTV (sMTV) heavily influenced tMTV value, particularly case diffuse uptake included calculation. High could a negative prognostic factor as represents tumor burden. On this basis, aim current was evaluate effect sMTV defined on baseline PET calculation its impact outcome, 5y-PFS (Progression Free Survival), follicular lymphoma patients. Methods Results: Overall, 690 with were analysis, 48% older than 60 years, 89% had stage III-IV disease 40% high-risk FLIPI-2 score. 79% (95% CI, 76%–82%). Among 469 (67.9%) did not have involvement while 128 (18.5%) 93 (13.4%) showed focal involvement, respectively. The CI) according status 67% (62–72), 58% (48–67) 61% (49–61) without, respectively (p significant). performed threshold 41% for segmentation. In whole population patients, categorized low high burden 224 194 ml without sMTV, Assuming 200 threshold, only 16/693 pts (2.3%) changed from when tMTV. Including tMTV, ml, 73% CI: 67–78) 53–64), respectively, HR 1.83 < 0.001). Excluding 72% 67–77) 52–64) 1.80 two groups, HRs values >200 negligible difference, independently inclusion. Conclusion: These preliminary data correlated outcome terms PFS; contrary metabolic do seem show any added neither nor uptake. Finally, inclusion/exclusion into significantly change either risk classification or PFS. Larger are needed confirm these data. References: R. Durmo, L. Guerra, S. Chauvie et al. “Total dissemination calculated PET/CT scan first line therapy predictors lymphoma” Eur J Nucl Med Mol Imaging (2022) 49 (Suppl 1): S1–S751; OP 629 Keywords: Diagnostic Prognostic Biomarkers, PET-CT No conflicts interests pertinent abstract.